Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28532829 | 0.98 | APLNR (0.49) | APLNRHTR6KMT2AHTR2AMAPT | |
| SCHEMBL10799767 | 0.95 | MAPT (0.45) | APLNRHTR6KMT2AHTR2AMAPT | |
| SCHEMBL10800370 | 0.91 | APLNR (0.45) | APLNRHTR6KMT2AHTR2ACXCR2 | |
| Fumaric Acid SCHEMBL11022713 | 0.90 | KMT2A (0.43) | APLNRHTR6KMT2ACXCR2 | |
| Maleic Acid SCHEMBL11022706 | 0.90 | KMT2A (0.43) | APLNRHTR6KMT2ACXCR2 | |
| SCHEMBL336837 | 0.89 | HTR2A (0.45) | HTR6HTR2AMAPTCXCR2HTR2C | |
| Hydrochloric Acid SCHEMBL10794547 | 0.89 | APLNR (0.44) | APLNRHTR6KMT2AHTR2ACXCR2 | |
| Hydrochloric Acid SCHEMBL3547060 | 0.88 | HTR2A (0.44) | HTR6KMT2AHTR2AMAPTCXCR2 | |
| SCHEMBL10797750 | 0.87 | MMP8 (0.60) | APLNRHTR6KMT2ACXCR2MMP8 | |
| SCHEMBL10797246 | 0.86 | HTR2A (0.46) | HTR6HTR2AMAPTMMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4642348-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-02-10 | — | — | US | claimed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | claimed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| CN-108112251-A | NRF2 conditioning agents | 葛兰素史克知识产权发展有限公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-2236494-B1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD KK (JP) | 2016-08-31 | — | — | EP | disclosed |
| CN-102036953-B | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| US-8124807-B2 | Sulfonyl-substituted 6-membered ring derivative | MSD K.K. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-2236494-A1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-4642348-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-02-10 | — | — | US | disclosed |
| US-4593102-A | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | CHRM2, CHRM3, CHRM1 | APLNR 1495/4885HTR6 26/4885KMT2A 1869/4885 |
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | APLNR 2889/4885HTR6 1613/4885KMT2A 1359/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | APLNR 2306/4885HTR6 1488/4885KMT2A 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.